Are we there yet? Leveraging the Private Sector for Lassa Vaccine R&D
The search for an effective vaccine against Lassa fever has gained momentum in recent years. Currently, early supportive care and the anti-viral drug Ribavirin are the primary methods of patient treatment. Lassa fever has long been a public health concern in Nigeria and parts of West Africa, since the disease was first identified in 1969. […]
Read More
20 Oct




